AU2013336409B2 - Drug-protein conjugates - Google Patents

Drug-protein conjugates Download PDF

Info

Publication number
AU2013336409B2
AU2013336409B2 AU2013336409A AU2013336409A AU2013336409B2 AU 2013336409 B2 AU2013336409 B2 AU 2013336409B2 AU 2013336409 A AU2013336409 A AU 2013336409A AU 2013336409 A AU2013336409 A AU 2013336409A AU 2013336409 B2 AU2013336409 B2 AU 2013336409B2
Authority
AU
Australia
Prior art keywords
group
conjugate
linker
formula
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013336409A
Other languages
English (en)
Other versions
AU2013336409A1 (en
Inventor
George Badescu
John Burt
Mark Frigerio
Antony Godwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abzena UK Ltd
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2013/051593 external-priority patent/WO2013190292A2/en
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of AU2013336409A1 publication Critical patent/AU2013336409A1/en
Application granted granted Critical
Publication of AU2013336409B2 publication Critical patent/AU2013336409B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
AU2013336409A 2012-10-24 2013-10-11 Drug-protein conjugates Active AU2013336409B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261717710P 2012-10-24 2012-10-24
US201261717743P 2012-10-24 2012-10-24
US61/717,710 2012-10-24
US61/717,743 2012-10-24
US201361811285P 2013-04-12 2013-04-12
US61/811,285 2013-04-12
AUPCT/GB2013/051593 2013-06-19
PCT/GB2013/051593 WO2013190292A2 (en) 2012-06-19 2013-06-19 Novel process for preparation of antibody conjugates and novel antibody conjugates
PCT/GB2013/052661 WO2014064423A1 (en) 2012-10-24 2013-10-11 Drug-protein conjugates

Publications (2)

Publication Number Publication Date
AU2013336409A1 AU2013336409A1 (en) 2015-04-02
AU2013336409B2 true AU2013336409B2 (en) 2017-08-03

Family

ID=50544085

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013336409A Active AU2013336409B2 (en) 2012-10-24 2013-10-11 Drug-protein conjugates

Country Status (18)

Country Link
US (2) US20150290342A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2911700B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6328648B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102209395B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104870021B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013336409B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015008376A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2884299A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2911700T5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2623209T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL237672B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015DN02349A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2015005122A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY169147A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2015119561A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201501618WA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014064423A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201501642B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015156888A (ru) 2013-06-04 2017-07-14 Сайтомкс Терапьютикс, Инк. Композиции и методы конъюгирования активируемых антител
AU2014337555C1 (en) 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
EP3145552B1 (en) * 2014-05-23 2020-03-04 Novartis AG Methods for making conjugates from disulfide-containing proteins
AU2015274506C1 (en) * 2014-06-12 2022-10-13 CSPC Megalith Biopharmaceutical Co., Ltd. Homogenous antibody drug conjugates via enzymatic methods
WO2016059377A1 (en) * 2014-10-14 2016-04-21 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
BR112017005760A2 (pt) * 2014-10-24 2017-12-12 Polytherics Ltd conjugados e reagentes de conjugação
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
JP6486316B2 (ja) 2015-11-03 2019-03-20 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗体−薬物複合体（ａｄｃ）およびそれを形成するための方法
JP2019501131A (ja) 2015-12-04 2019-01-17 シアトル ジェネティックス， インコーポレイテッド 四級化チューブリシン化合物の複合体
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
KR20180134351A (ko) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
EP3442595A1 (en) * 2016-04-14 2019-02-20 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
GB201608936D0 (en) * 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
WO2017212250A1 (en) * 2016-06-06 2017-12-14 Polytherics Limited Antibodies, uses thereof and conjugates thereof
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
AU2018237683A1 (en) 2017-03-24 2019-10-31 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
GB201820864D0 (en) * 2018-12-20 2019-02-06 J A Kemp Antibody-drug conjugates
EP4117729A4 (en) * 2020-04-15 2023-11-15 Shenzhen Enduring Biotech, Ltd. ANTIBODY-DRUG CONJUGATE
JP2024510760A (ja) * 2021-03-19 2024-03-11 シェンチェン・エンデュアリング・バイオテック・リミテッド Ｃｄ３およびｃｄ１９に二重特異性を有するｐｅｇ化ｔ細胞エンゲージャー
WO2023141855A1 (en) * 2022-01-27 2023-08-03 Glyco-Therapy Biotechnology Co., Ltd. Protein conjugates with multiple payloads and methods for making the same
TW202444426A (zh) * 2023-03-29 2024-11-16 美商艾克塞里克斯公司 Amhrii抗體-藥物結合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013190292A2 (en) * 2012-06-19 2013-12-27 Polytherics Limited Novel process for preparation of antibody conjugates and novel antibody conjugates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2557389T3 (es) * 2003-11-06 2016-01-25 Seattle Genetics, Inc. Compuestos de monometilvalina conjugados con anticuerpos
JP5290756B2 (ja) * 2005-09-26 2013-09-18 メダレックス インコーポレイテッド 抗体−薬剤コンジュゲート及びその使用
SI2211904T1 (sl) * 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
EP2842575B1 (en) 2008-03-18 2017-09-27 Seattle Genetics, Inc. Auristatin drug linker conjugates
MX2010011808A (es) * 2008-04-30 2011-03-04 Immunogen Inc Conjugados potentes y enlazadores hidrofilicos.
WO2010100430A1 (en) 2009-03-04 2010-09-10 Polytherics Limited Conjugated proteins and peptides
NZ595574A (en) * 2009-04-01 2013-11-29 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
AR078471A1 (es) * 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
JP6384963B2 (ja) * 2012-04-25 2018-09-05 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 勾配コイルを置くためのシステム及び方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013190292A2 (en) * 2012-06-19 2013-12-27 Polytherics Limited Novel process for preparation of antibody conjugates and novel antibody conjugates

Also Published As

Publication number Publication date
ES2623209T3 (es) 2017-07-10
DK2911700T3 (en) 2017-05-15
BR112015008376A2 (pt) 2017-09-26
EP2911700A1 (en) 2015-09-02
DK2911700T5 (en) 2017-05-22
KR102209395B1 (ko) 2021-01-28
JP6328648B2 (ja) 2018-05-23
IN2015DN02349A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-08-28
IL237672A0 (en) 2015-04-30
EP2911700B1 (en) 2017-02-08
IL237672B (en) 2018-02-28
CN104870021B (zh) 2018-03-13
SG11201501618WA (en) 2015-04-29
HK1208187A1 (en) 2016-02-26
JP2015533847A (ja) 2015-11-26
ZA201501642B (en) 2016-01-27
US20220062436A1 (en) 2022-03-03
WO2014064423A1 (en) 2014-05-01
CA2884299A1 (en) 2014-05-01
AU2013336409A1 (en) 2015-04-02
RU2015119561A (ru) 2016-12-20
EP3159013A1 (en) 2017-04-26
US20150290342A1 (en) 2015-10-15
CN104870021A (zh) 2015-08-26
MY169147A (en) 2019-02-18
KR20150103656A (ko) 2015-09-11
MX2015005122A (es) 2015-10-29

Similar Documents

Publication Publication Date Title
AU2013336409B2 (en) Drug-protein conjugates
AU2013336410B2 (en) Drug-protein conjugates
US20200392108A1 (en) Antibody-drug conjugates and related compounds, compositions and methods
KR101988005B1 (ko) 개선된 연결을 갖는 아마톡신-접합체
KR20230008723A (ko) 전하 변이체 링커
AU2015340370A1 (en) Materials and methods relating to linkers for use in protein drug conjugates
HK1232455A1 (en) Drug-protein conjugates
HK1232455A (en) Drug-protein conjugates
HK1208187B (en) Drug-protein conjugates
HK1208186B (en) Drug-protein conjugates
NZ728857B2 (en) Materials and methods relating to linkers for use in protein drug conjugates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)